Photodynamic therapy: current role in the treatment of chorioretinal conditions

Newman, D K

doi:10.1038/eye.2015.251

Cited by 88 publications

(95 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From both libraries (101,200 compounds), the most effective inhibitor is verteporfin, which is an FDA-approved drug for macular degeneration of eyes (25). The formula of verteporfin is C 41 H 42 N 4 O 8 .…”

Section: Methodsmentioning

confidence: 99%

“…Besides the above 100,000 molecules, 1200 compounds of an FDA-approved drug library were also tested using the same cell-based (.90% inhibition) and in vitro screening approaches. From both libraries (101,200 compounds), the most effective inhibitor is verteporfin, which is an FDA-approved drug for macular degeneration of eyes (25). The formula of verteporfin is C 41 H 42 N 4 O 8 .…”

Section: Cell-based High-throughput Screening and In Vitro Kinase Scrmentioning

confidence: 99%

See 1 more Smart Citation

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK ^high IL‐17A ^high subpopulation of systemic lupus erythematosus

Chuang

Chen

et al. 2019

FASEB j.

View full text Add to dashboard Cite

The cytokine IL‐17A plays critical roles in the pathogenesis of autoimmune diseases. The frequencies of MAP kinase kinase kinase kinase 3 [also named germinal center kinase–like kinase (GLK)]‐overexpressing T cells are correlated with disease severity of systemic lupus erythematosus (SLE). T‐cell–specific GLK‐transgenic mice develop spontaneous autoimmune responses through IL‐17A. GLK signaling selectively stimulates IL‐17A production in murine T cells through inducing aryl hydrocarbon receptor (AhR)–retinoic acid receptor–related orphan nuclear receptor‐³t (ROR‐³t) complex formation. Here, we investigated whether GLK‐induced AhR–ROR‐³t complex in T cells is a therapeutic target for human SLE. The population of GLK+IL‐17A+ T cells was enhanced in the peripheral blood from patients with SLE compared with that of healthy controls using flow cytometry. The receiver operating characteristic curve analysis showed that increased GLK+IL‐17A+ T‐cell population in peripheral blood reflected an active stage of SLE. In addition, peripheral blood T cells from patients with SLE displayed induction of ROR‐³t phosphorylation and the AhR‐ROR‐³t (and AhR–phosphorylated ROR‐³t) complex. Moreover, we identified a small‐molecule inhibitor, verteporfin, that inhibited GLK kinase activity and AhR–ROR‐³t interaction. The small‐molecule inhibitor verteporfin suppressed the disease severity in autoimmune mouse models and IL‐17A production in T cells from patients with SLE. Collectively, the GLK‐induced AhR‐ROR‐³t (and AhR–phosphorylated ROR‐³t) complex is a therapeutic target for the GLKhighIL‐17Ahigh subpopulation of human patients with SLE.—Chuang, H.‐C, Chen, Y.‐M., Chen, M.‐H., Hung, W.‐T., Yang, H.‐Y., Tseng, Y.‐H., Tan, T.‐H. AhR‐ROR‐³t complex is a therapeutic target for MAP4K3/GLKhighIL‐17Ahigh subpopulation of systemic lupus erythematosus. FA8EB J. 33, 11469–11480 (2019). http://www.fasebj.org

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Cell-based High-throughput Screening and In Vitro Kinase Scrmentioning

confidence: 99%

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK ^high IL‐17A ^high subpopulation of systemic lupus erythematosus

Chuang

Chen

et al. 2019

FASEB j.

View full text Add to dashboard Cite

show abstract

“…PDT can damage the CNV framework that is insensitive to anti-VEGF drugs. Combined with Lucentis, PDT can enlarge the CNV blocking degree and prevent any further damage to vision (15). The simple Lucentis intravitreal injection needs to be repeated many times to achieve an ideal effect, during which it can result in amotio retinae, increase of intra-ocular pressure, traumatic cataracts and other ocular complications (16).…”

Section: Discussionmentioning

confidence: 99%

Effect of anti-VEGF drugs combined with photodynamic therapy in the treatment of age-related macular degeneration

Dong

Wan

Yan

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

We analyzed the effects of anti-vascular endothelial growth factor (VEGF) drugs combined with photodynamic therapy (PDT) in the treatment of age-related macular degeneration (AMD). Ninety-six cases (192 eyes) of AMD were included in this study and randomly divided into the observation group and control group (n=48 cases per group). The control group was administered the treatment of Lucentis intravitreal injection alone and the observation group was administered Lucentis combined with PDT. The therapeutic effects were compared. The best corrected visual acuity of patients in the two groups increased gradually after treatment. Patients in the observation group had a significantly higher visual acuity when compared to the control group 1 and 6 months post-operation. The differences were statistically significant (P<0.05). The proportion of patients with vision improvement in the observation group was higher than that in the control group from 1 to 6 months; differences were statistically significant (P<0.05). Through detection by color Doppler ultrasound within 6 months after treatment, we observed that the peak systolic velocity and arterial end diastolic velocity of retrobulbar optic nerve bitemporal PCA of the observation group were higher than those of the control group. The values of arterial resistance index and pulsatility index of the observation group were lower than those of control group. The differences were statistically significant (P<0.05). Six months after treatment, the value of central foveal thickness of the observation group was lower than that of the control group, the value of mean sensitivity of visual field parameter 10° and 4° was higher in the observation group than in the control group, and the absolute value of mean defects in the observation group were lower than that of the control group. In summary, the differences were statistically significant (P<0.05). Anti-VEGF drugs combined with PDT can optimize the overall vision of patients with AMD, improve hemodynamic parameters and reduce visual field defects.

show abstract

“…The photoexcitation of verteporfin produces reactive oxygen species, leading to endothelial cell damage, platelet aggregation, activation of the clotting cascade, and microvascular occlusion [27]. Selective vascular occlusion is achieved by the concentration of verteporfin in the abnormal and hyperpermeable choroidal endothelium [28]. The effica cy of half-dose PDT on CSC, therefore, depends on its thrombotic action on the hyperpermeable choroidal vasculature.…”

Section: Discussionmentioning

confidence: 99%

Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy

Chung

Chan

2018

Ophthalmologica

View full text Add to dashboard Cite

Aims: To identify the angiographic and tomographic prognostic factors of chronic central serous chorioretinopathy (CSC) treated with half-dose photodynamic therapy (PDT). Methods: This is a consecutive series of 61 eyes with chronic CSC treated with half-dose PDT from January 1, 2009 to October 31, 2016. Results: The mean logMAR best-corrected visual acuity (BCVA) improved from 0.47 to 0.31 at 3 months (p < 0.001). From multivariate regression, the final BCVA was significantly associated with the baseline BCVA (p = 0.003), a diffuse hyperfluorescence pattern on indocyanine green angiography (ICGA) (p = 0.024), posttreatment shallow irregular pigment epithelium detachment (PED) (p = 0.022), and disruption of the ellipsoid zone (p = 0.007). A diffuse hyperfluorescence pattern on ICGA was associated with a 77.4 times risk of subretinal fluid persistence after treatment (p = 0.009). Conclusion: A poor baseline BCVA, diffuse hyperfluorescence ICGA pattern, shallow irregular PED, and disruption of the ellipsoid zone indicate poor prognosis.

show abstract

Photodynamic therapy: current role in the treatment of chorioretinal conditions

Cited by 88 publications

References 78 publications

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK ^high IL‐17A ^high subpopulation of systemic lupus erythematosus

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK ^high IL‐17A ^high subpopulation of systemic lupus erythematosus

Effect of anti-VEGF drugs combined with photodynamic therapy in the treatment of age-related macular degeneration

Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy

Contact Info

Product

Resources

About

Photodynamic therapy: current role in the treatment of chorioretinal conditions

Cited by 88 publications

References 78 publications

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK high IL‐17A high subpopulation of systemic lupus erythematosus

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK high IL‐17A high subpopulation of systemic lupus erythematosus

Effect of anti-VEGF drugs combined with photodynamic therapy in the treatment of age-related macular degeneration

Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy

Contact Info

Product

Resources

About

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK ^high IL‐17A ^high subpopulation of systemic lupus erythematosus

AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK ^high IL‐17A ^high subpopulation of systemic lupus erythematosus